期刊文献+

1例抗磷脂综合征反复支架内再狭窄患者抗栓药物治疗管理 被引量:1

Management of antithrombotic therapy in a patient with antiphospholipid syndrome and recurrent in-stent restenosis
原文传递
导出
摘要 抗磷脂综合征(antiphospholipid syndrome,APS)是一种系统性自身免疫性疾病,是较常见的血液高凝状态的原因,临床可见反复的动静脉血栓形成^([1])。对于合并动脉血栓形成的APS患者,指南建议华法林抗凝甚至联合阿司匹林抗血小板治疗^([2])。
作者 韩丽珠 胡扬 尹琪楠 王鹏伟 陈怡然 边原 HAN Li-zhu;HU Yang;YIN Qi-nan;WANG Peng-wei;CHEN Yi-ran;BIAN Yuan(Department of Pharmacy,Sichuan Academy of Medical Sciences&Sichuan Provincial People's Hospital/Personalized Drug Therapy Key Laboratory of Sichuan Province,Affiliated Hospital of University of Electronic Science and Technology of China,Chengdu SICHUAN 610072,China;Peking Union Medical College Hospital,Chinese Academy of Medical Sciences,BEIJING 100730,China;Department of Pharmacy,the First Afiliated Hospital of Xinxiang Medical University,Xinxiang HE-NAN 453100,China)
出处 《中国新药与临床杂志》 CAS CSCD 北大核心 2023年第5期323-325,共3页 Chinese Journal of New Drugs and Clinical Remedies
基金 国家重点研发计划(2020YFC2005506) 个体化药物治疗四川省重点实验室开放课题(2021ZD01) 四川省干部保健科研课题(川干研2021-226) 四川省医学会静脉血栓栓塞症防治专项科研课题(2019HR02) 四川省科技厅自然科学基金(2022NSFSC0818)。
关键词 冠状动脉再狭窄 抗磷脂综合征 血栓形成 氯吡格雷 coronary restenosis antiphospholipid syndrome thrombosis clopidogrel
  • 相关文献

参考文献3

二级参考文献17

  • 1胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 2Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 3Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 4Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 5Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 6Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 7Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 8Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.
  • 9Manolopoulos VG, Ragia G, Tavridou A. Pharmacogenetics of coumarinic oral anticoagulants. Pharmacogenomics, 2010, 11 : 493 -496.
  • 10Schulman S, Parpia S, Stewart C, et al. Warfarin dose assessment every 4 weeks versus every 12 weeks in patients with stable international normalized ratios: a randomized trial. Ann Intern Med, 2011,155:653-659.

共引文献1449

同被引文献11

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部